BACKGROUND: Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens. METHODS: In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic syndromes were randomly assigned one-to-one to receive azacitidine (75 mg/m(2) per day for 7 days every 28 days) or conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy as selected by investigators before randomisation). Patients were stratified by French-American-British and international prognostic scoring system classifications; randomisation was done with a block size of four. The primary endpoint was overall survival. Efficacy analyses were by intention to treat for all patients assigned to receive treatment. This study is registered with ClinicalTrials.gov, number NCT00071799. FINDINGS:Between Feb 13, 2004, and Aug 7, 2006, 358 patients were randomly assigned to receive azacitidine (n=179) or conventional care regimens (n=179). Four patients in the azacitidine and 14 in the conventional care groups received no study drugs but were included in the intention-to-treat efficacy analysis. After a median follow-up of 21.1 months (IQR 15.1-26.9), median overall survival was 24.5 months (9.9-not reached) for the azacitidine group versus 15.0 months (5.6-24.1) for the conventional care group (hazard ratio 0.58; 95% CI 0.43-0.77; stratified log-rank p=0.0001). At last follow-up, 82 patients in the azacitidine group had died compared with 113 in the conventional care group. At 2 years, on the basis of Kaplan-Meier estimates, 50.8% (95% CI 42.1-58.8) of patients in the azacitidine group were alive compared with 26.2% (18.7-34.3) in the conventional care group (p<0.0001). Peripheral cytopenias were the most common grade 3-4 adverse events for all treatments. INTERPRETATION: Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care.
RCT Entities:
BACKGROUND: Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens. METHODS: In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic syndromes were randomly assigned one-to-one to receive azacitidine (75 mg/m(2) per day for 7 days every 28 days) or conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy as selected by investigators before randomisation). Patients were stratified by French-American-British and international prognostic scoring system classifications; randomisation was done with a block size of four. The primary endpoint was overall survival. Efficacy analyses were by intention to treat for all patients assigned to receive treatment. This study is registered with ClinicalTrials.gov, number NCT00071799. FINDINGS: Between Feb 13, 2004, and Aug 7, 2006, 358 patients were randomly assigned to receive azacitidine (n=179) or conventional care regimens (n=179). Four patients in the azacitidine and 14 in the conventional care groups received no study drugs but were included in the intention-to-treat efficacy analysis. After a median follow-up of 21.1 months (IQR 15.1-26.9), median overall survival was 24.5 months (9.9-not reached) for the azacitidine group versus 15.0 months (5.6-24.1) for the conventional care group (hazard ratio 0.58; 95% CI 0.43-0.77; stratified log-rank p=0.0001). At last follow-up, 82 patients in the azacitidine group had died compared with 113 in the conventional care group. At 2 years, on the basis of Kaplan-Meier estimates, 50.8% (95% CI 42.1-58.8) of patients in the azacitidine group were alive compared with 26.2% (18.7-34.3) in the conventional care group (p<0.0001). Peripheral cytopenias were the most common grade 3-4 adverse events for all treatments. INTERPRETATION: Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care.
Authors: David Bowen; Dominic Culligan; Simon Jowitt; Stephen Kelsey; Ghulam Mufti; David Oscier; Jane Parker Journal: Br J Haematol Date: 2003-01 Impact factor: 6.998
Authors: E H Estey; P F Thall; J E Cortes; F J Giles; S O'Brien; S A Pierce; X Wang; H M Kantarjian; M Beran Journal: Blood Date: 2001-12-15 Impact factor: 22.113
Authors: Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: Emilio Paolo Alessandrino; Sergio Amadori; Giovanni Barosi; Mario Cazzola; Alberto Grossi; Lucio N Liberato; Franco Locatelli; Monia Marchetti; Enrica Morra; Paolo Rebulla; Giuseppe Visani; Sante Tura Journal: Haematologica Date: 2002-12 Impact factor: 9.941
Authors: W K Hofmann; G Heil; C Zander; S Wiebe; O G Ottmann; L Bergmann; K Hoeffken; J T Fischer; A Knuth; K Kolbe; H J Schmoll; W Langer; M Westerhausen; C B Koelbel; D Hoelzer; A Ganser Journal: Ann Hematol Date: 2004-05-20 Impact factor: 3.673
Authors: Thomas Prébet; Sophie Ducastelle; Stephan Debotton; Aspasia Stamatoullas; Eric Deconinck; Christophe Fruchart; Nicole Gratecos; Norbert Ifrah; François Dreyfus; Pierre Fenaux; Eric Wattel Journal: Hematol J Date: 2004
Authors: Y Boumber; H Kantarjian; J Jorgensen; S Wen; S Faderl; R Castoro; J Autry; G Garcia-Manero; G Borthakur; E Jabbour; Z Estrov; J Cortes; J-P Issa; F Ravandi Journal: Leukemia Date: 2012-06-05 Impact factor: 11.528
Authors: John F Seymour; Pierre Fenaux; Lewis R Silverman; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Alan F List; Steven D Gore; Jay Backstrom; David McKenzie; C L Beach Journal: Crit Rev Oncol Hematol Date: 2010-05-06 Impact factor: 6.312
Authors: Guillermo Garcia-Manero; Elizabeth A Griffiths; David P Steensma; Gail J Roboz; Richard Wells; James McCloskey; Olatoyosi Odenike; Amy E DeZern; Karen Yee; Lambert Busque; Casey O'Connell; Laura C Michaelis; Joseph Brandwein; Hagop Kantarjian; Aram Oganesian; Mohammad Azab; Michael R Savona Journal: Blood Date: 2020-08-06 Impact factor: 22.113